Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-874 in Multiple Sclerosis
NCT00086671Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2004
- Primary completion
- Nov 2006
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of briakinumab in multiple sclerosis (MS), sponsored by AbbVie Inc.. Started Apr 2004; status: completed.
02
Drugs
briakinumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00086671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086671.